Answer
B.
Surgery in patients with one N2 lymph node station involved by a lymph node smaller than 3 cm.
Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.
Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.
Answer and Question 2 on Next Page »
B.
Surgery in patients with one N2 lymph node station involved by a lymph node smaller than 3 cm.
This practice pattern was selected by 90.5% of the member institutions, according to the NCCN. In addition, 80% said they would use endobronchial ultrasound with or without endoscopic ultrasound in initial evaluation of the mediastinum, and 40.5% noted they would use pathologic evaluation of the mediastinum, after neoadjuvant therapy, to make a final decision before surgery.
Answer and Question 3 on Next Page »
C.
5 cm
The guidelines note that such patients should be counseled about the subsequent risk of locoregional and distant failure.
Answer and Question 4 on Next Page »
C.
Race
The study found that half of patients alive at 5 years were alive at 10 years, with 10-year survival “associated with younger age, earlier stage, non-squamous histology, lobectomy, and fewer comorbidities, but not race.”
Answer and Question 5 on Next Page »
B.
True
The study compared overall survival and lung cancer–specific survival among patients after lobectomy, segmentectomy, or wedge resection.
Answer on Next Page »
D.
All of the above
VATS is also associated with a shorter length of hospitalization, minimal locoregional recurrence, and improved discharge independence in older and high-risk patients, according to the guidelines.
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy
November 21st 2024In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.